Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Exenatide: pharmacokinetics, clinical use, and future directions

Research output: Contribution to journalReviewResearchpeer-review

  1. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Non-insulin pharmacological therapies for treating type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Management of cardiovascular disease in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction - a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: The first-in-class glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide, which was initially approved in 2005, is available in twice-daily (BID) and once-weekly (QW) formulations. Clinical trial data suggest both formulations are effective and safe for patients with type 2 diabetes (T2D), both as monotherapy and as part of combination therapy. Since exenatide was approved, several other GLP-1RAs have become available for clinical use. Areas covered: Many ongoing clinical trials involving exenatide BID and exenatide QW are investigating new indications (exenatide BID) and new end points and combination therapies (exenatide QW). This review provides an overview of the delivery and pharmacokinetics of both formulations of exenatide, reviews existing data in T2D, and summarizes ongoing investigations. Expert opinion: Exenatide BID and QW have substantial clinical benefits. Comparisons with other GLP-1RAs demonstrate some differences in efficacy and safety profiles that make assessment of benefit:risk ratios complex. Head-to-head comparisons of QW GLP-1RA formulations may assist in the ranking of GLP-1RAs according to efficacy and safety. Results on the impact of exenatide QW on cardiovascular outcomes are eagerly awaited. The potential clinical utility of exenatide BID in other indications will clarify whether exenatide holds clinical promise in diagnoses other than T2D.

Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number6
Pages (from-to)555-571
Number of pages17
ISSN1465-6566
DOIs
Publication statusPublished - Apr 2017

    Research areas

  • Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Glycated Hemoglobin A, Humans, Hypoglycemic Agents, Peptides, Venoms, Journal Article, Review

ID: 52661570